Envisioned as a hub for accelerating the journey from laboratory research to clinical application, the Cancer Bioengineering Collaborative leverages the complementary strengths of The University of Texas MD Anderson Cancer Center and Rice University to drive discovery and innovation in five key research areas:
- Cell therapies: Developing more effective cell-based immunotherapies, including chimeric antigen receptor T-cell therapy and T-cell receptor-based approaches
- Nanotechnologies: Using nanoparticles for targeted cancer detection and therapy
- Cancer vaccines: Incorporating advanced biomaterials, synthetic biology, and nanoparticle delivery systems to develop therapeutic vaccines
- Artificial intelligence: Leveraging advanced computing tools for unbiased, high-precision analyses of samples to identify new targets and inform therapeutic design
- Molecular imaging: Deploying advanced molecular imaging techniques to enhance diagnostic and therapeutic tools